Pharma Trends and Predictions for 2025: An incoming CEO’s perspective

Elizabeth Hickman, CEO of AustinPx, outlines six key trends shaping the CDMO landscape in 2025. From the rise of GLP-1s and AI-driven molecules to growing interest in patient-centric dosage forms and IP-enhancing services, the article highlights how CDMOs must evolve to stay competitive. Hickman emphasizes the need for advanced formulation technologies, scalable processes, and a balance of scientific rigor and client-focused service. CDMOs that can reduce cost, accelerate timelines, and offer real value beyond manufacturing will be best positioned for the year ahead.